Key Points
- EVP Brenton Taylor sold 14,418 shares of Sight Sciences on November 17 at an average price of $7.06 for about $101,791, reducing his stake by 7.78% to 170,831 shares valued at roughly $1.21 million.
- Sight Sciences remains unprofitable, reporting ($0.81) EPS last quarter with a negative net margin of ~60.63% and negative ROE of 61.59%, and analysts forecast about -0.99 EPS for the current fiscal year.
- The stock has a market cap of ~$377.5M, a 52-week range of $2.03–$8.06 and 50/200-day moving averages of $4.49/$4.02, while the consensus analyst rating is "Hold" with an average target price of $5.17.
Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) EVP Brenton Taylor sold 14,418 shares of the firm's stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $7.06, for a total value of $101,791.08. Following the transaction, the executive vice president owned 170,831 shares of the company's stock, valued at $1,206,066.86. This trade represents a 7.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Brenton Taylor also recently made the following trade(s):
- On Monday, October 6th, Brenton Taylor sold 591 shares of Sight Sciences stock. The shares were sold at an average price of $3.37, for a total value of $1,991.67.
Sight Sciences Stock Performance
Shares of NASDAQ:SGHT opened at $7.14 on Wednesday. The stock has a market capitalization of $377.49 million, a price-to-earnings ratio of -7.93 and a beta of 2.47. The business's fifty day moving average price is $4.49 and its two-hundred day moving average price is $4.02. Sight Sciences, Inc. has a fifty-two week low of $2.03 and a fifty-two week high of $8.06. The company has a debt-to-equity ratio of 0.62, a current ratio of 9.60 and a quick ratio of 8.93.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Wednesday, September 8th. The company reported ($0.81) EPS for the quarter. Sight Sciences had a negative net margin of 60.63% and a negative return on equity of 61.59%. The firm had revenue of $12.54 million during the quarter. As a group, analysts predict that Sight Sciences, Inc. will post -0.99 EPS for the current fiscal year.
Hedge Funds Weigh In On Sight Sciences
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. KCK LTD. bought a new stake in Sight Sciences in the second quarter valued at about $18,069,000. Long Focus Capital Management LLC boosted its position in shares of Sight Sciences by 39.7% during the first quarter. Long Focus Capital Management LLC now owns 3,126,508 shares of the company's stock worth $7,504,000 after purchasing an additional 887,876 shares in the last quarter. Americana Partners LLC bought a new stake in shares of Sight Sciences in the 2nd quarter valued at $3,568,000. Acadian Asset Management LLC raised its stake in Sight Sciences by 127.7% during the 1st quarter. Acadian Asset Management LLC now owns 432,541 shares of the company's stock worth $1,033,000 after buying an additional 242,559 shares during the period. Finally, Vanguard Group Inc. lifted its holdings in Sight Sciences by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,906,696 shares of the company's stock worth $6,559,000 after acquiring an additional 102,609 shares in the last quarter. 55.51% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on SGHT shares. Citigroup dropped their price target on Sight Sciences from $4.50 to $4.00 and set a "neutral" rating for the company in a report on Tuesday, October 7th. Morgan Stanley increased their target price on Sight Sciences from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Monday, November 10th. Weiss Ratings restated a "sell (d-)" rating on shares of Sight Sciences in a research note on Wednesday, October 8th. Lake Street Capital increased their price objective on shares of Sight Sciences from $5.00 to $7.00 and gave the stock a "buy" rating in a report on Tuesday, October 21st. Finally, Wall Street Zen upgraded shares of Sight Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, September 13th. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $5.17.
Check Out Our Latest Analysis on Sight Sciences
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
